Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Injectable use depends on compounding rules, which shifted in 2026
doi:10.1016/0306-9877(88)90082-5
Tirzepatide Dual agonist : GLP-1 + GIP Central benchmark for dual incretin research Often discussed in relation to body-weight outcomes, glycaemic control and incretin signalling Single agonist : GLP-1 More selective and mechanistically narrower Common reference point for GLP-1 pathway research Triple agonist : GLP-1 + GIP + glucagon Broader receptor profile than Tirzepatide Often discussed in relation to weight loss, energy expenditure and next-generation multi-pathway metabolic modulation For researchers comparing incretin classes, Tirzepatide often functions as the middle reference point between single-pathway GLP-1 agonists and broader triple-agonist designs
basis for ophthalmic applications (PMID: 19668473) Muscle: Improved muscle regeneration following injury
Rather than injecting large doses infrequently (most of which you will flush out within an hour), its much better to inject smaller, daily doses
